Correspondence
Pau Sancho‐Bru, José Altamirano, Ramon Bataller – 17 May 2012
Reply:
Kiran Bambha, Nathan M. Bass – 17 May 2012
Crosstalk between the hepatologist and the cardiologist: A future place for the lithocholic acid as a coronary atheroma risk factor?
Henri Duboc, Hélène Aelion, Dominique Rainteau, Sylvie Rajca, Harry Sokol, Lydie Humbert, Dominique Farabos, Benoit Coffin, Simon Weber, Raphaël Porcher, Olivier Varenne, Denis Duboc – 17 May 2012
Hedgehog‐responsive progenitors: Predictors of liver outcomes?
Jason Coombes, Wing‐Kin Syn – 17 May 2012
Resection of hepatocellular cancer ≤2 cm: Results from two Western centers
Sasan Roayaie, Khaled Obeidat, Carlo Sposito, Luigi Mariani, Sherrie Bhoori, Alessandro Pellegrinelli, Daniel Labow, Josep M. Llovet, Myron Schwartz, Vincenzo Mazzaferro – 11 May 2012 – Asian series have shown a 5‐year survival rate of ≈70% after resection of hepatocellular carcinoma (HCC) ≤2 cm. Western outcomes with resection have not been as good. In addition, ablation of HCC ≤2 cm has been shown to achieve competitive results, leaving the role of resection in these patients unclear.
Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers
Ellen Hulskotte, Samir Gupta, Fengjuan Xuan, Marga van Zutven, Edward O'Mara, Hwa‐Ping Feng, John Wagner, Joan Butterton – 11 May 2012 – The hepatitis C virus protease inhibitor boceprevir is a strong inhibitor of cytochrome P450 3A4 and 3A5 (CYP3A4/5). Cyclosporine and tacrolimus are calcineurin inhibitor immunosuppressants used to prevent organ rejection after liver transplantation; both are substrates of CYP3A4. This two‐part pharmacokinetic interaction study evaluated boceprevir with cyclosporine (part 1) and tacrolimus (part 2).
Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin‐induced apoptosis by inhibiting p53 activation
Lijuan Liu, Xiaobei Chen, Shuixiang Xie, Chuanjie Zhang, Zhenpeng Qiu, Fan Zhu – 11 May 2012 – KIAA0101 overexpression was detected in numerous malignant solid tumors and involved in tumor progression; however, the correlation between KIAA0101 expression level and human hepatocellular carcinoma (HCC) was controversial.
Outcomes after living donor liver transplantation for acute liver failure in Japan: Results of a nationwide survey
Noriyo Yamashiki, Yasuhiko Sugawara, Sumihito Tamura, Nobuaki Nakayama, Makoto Oketani, Koji Umeshita, Shinji Uemoto, Satoshi Mochida, Hirohito Tsubouchi, Norihiro Kokudo – 11 May 2012 – Nationwide surveys of acute liver failure (ALF) are conducted annually in Japan, and 20% of patients with ALF undergo liver transplantation (LT). We extracted data for 212 patients who underwent LT for ALF from the nationwide survey database of the Intractable Liver Diseases Study Group of Japan.
Comprehensive analysis for viral elements and interleukin‐28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection
Shinya Maekawa, Minoru Sakamoto, Mika Miura, Makoto Kadokura, Ryota Sueki, Kazuki Komase, Hiroko Shindo, Nobutoshi Komatsu, Kuniaki Shindo, Asuka Kanayama, Takako Ohmori, Fumitake Amemiya, Shinichi Takano, Tatsuya Yamaguchi, Yasuhiro Nakayama, Takatoshi Kitamura, Taisuke Inoue, Shunichi Okada, Nobuyuki Enomoto – 10 May 2012 – To comprehensively characterize the contribution of virological factors as well as interleukin‐28B (IL28B) single‐nucleotide polymorphisms (SNPs) in determining treatment responses in pegylated‐interferon plus ribavirin (Peg‐IFN/RBV) therapy for chronic hepatitis C vir